Human immunodeficiency virus (HIV)-related cellular immunodeficiency increases the risk of both primary and reactivated tuberculosis (TB) and is associated with greater likelihood of extrapulmonary and disseminated disease [1] . Rates of TB coinfection among people living with HIV (PLHIV) are highest in sub-Saharan Africa [2] , and TB is the leading cause of death among PLHIV globally [3] . Autopsy studies suggest that considerable proportions of HIV-related TB may be missed in TB-endemic settings [4] . Contributing factors for this are atypical disease presentation [5] and suboptimal performance of commonly available diagnostic methods for active TB, such as smear microscopy [6] and chest radiography [7] . A clinical symptom algorithm is recommended by the World Health Organization (WHO) for excluding TB among PLHIV [8] . Although this algorithm is sensitive, it has low specificity, limiting its usefulness as a screening tool [9] . Alternative strategies for screening in populations at high risk of TB could improve case finding.
These circumstances have prompted investigations of plasma biomarkers for identification of active TB. C-reactive protein (CRP) has been shown to have promising capacity as a pointof-care biomarker for TB screening among PLHIV in different settings [10] [11] [12] [13] [14] [15] . Although the capacity of panels of inflammatory markers for TB identification has been investigated [16] [17] [18] , this concept has not been assessed in a large PLHIV cohort systematically categorized for active TB. Because HIV leads to dysregulation of the TB immune response [19, 20] , we hypothesized that HIV-positive individuals with active TB have inflammatory reactions that could be used to distinguish such cases from HIV-positive persons without TB, and that combinations of inflammatory markers would provide stronger discriminatory capacity than single markers.
To explore this hypothesis, we designed a nested case-control study based on participants from a cohort of antiretroviral therapy (ART)-naive patients systematically investigated for active TB. We characterized plasma profiles of 9 markers of inflammation, selected on the basis of their previously reported associations with TB. We analyzed the performance for TB identification of these markers separately as well as in different combinations. Furthermore, we evaluated whether plasma levels of these markers were related to CD4 cell count and HIVribonucleic acid (RNA) levels, respectively.
METHODS

Study Participants
Participants for this study were identified from a prospective cohort of 812 HIV-positive adults subjected to intensified TB case finding before ART initiation at 5 public health centers in the Oromia region, Ethiopia (included between 2011 and 2013). Details of this cohort have been presented previously [9, 21] . In brief, for inclusion in the cohort, subjects were required to be ≥18 years old and meet Ethiopian criteria for ART initiation at the time of the study (CD4 cell count ≤350 cells/mm 3 and/or WHO stage 4). Individuals with previous ART experience and/ or ongoing treatment for TB for ≥2 weeks, as well as those who did not provide sputum samples for TB analyses, were excluded. At inclusion, cohort participants underwent physical examination and interview based on a structured questionnaire covering clinical and sociodemographic data. All subjects were instructed to submit 2 spontaneously expectorated morning sputum samples (irrespective of symptoms or physical findings), which were examined with Ziehl-Neelsen smear microscopy, liquid TB culture, and Xpert MTB/RIF (Cepheid, Sunnyvale, CA). Fine-needle aspirations were obtained from persons with lymphadenopathy. Venous blood was collected for analysis of CD4 cell count, complete blood count, and HIV RNA quantification. Aliquots of plasma were stored at −80°C and transported with intact cold chain to the Biomedical Center, Lund, Sweden, where laboratory analyses were undertaken after data collection and subject selection. A nested case-control design was chosen for the current study. All participants with bacteriologically confirmed TB (HIV + /TB + ) and available plasma samples were included as cases, and, for each of these, 1 control without active TB was selected, matched for age and gender (HIV + /TB − ). Plasma samples were available from 130 of 137 HIV + /TB + subjects. Control subjects (HIV + / TB − ) were required to have negative bacteriological results for TB and not to be diagnosed with bacteriologically confirmed nor clinically suspected TB during the first 6 months of follow-up. Participants without active TB at inclusion who were lost to follow-up or died within 6 months of follow-up were not eligible as controls, because unrecognized active TB could not be reliably excluded.
Quantification of Inflammatory Markers
Concentrations of inflammatory markers were determined using the Magnetic Luminex Assay (R&D Systems Inc. , backward stepwise logistic multivariate analysis was performed using continuous variables. From this multivariate analysis, predicted probabilities were calculated. A ROC curve describing sensitivity and specificity of the combination of markers that constituted the best model was then fitted. This model was subsequently assessed in an analysis of subjects with CD4 cell count <200/mm 3 . All statistical analyses were conducted using SPSS version 24.0 (IBM, Armonk, NY).
Ethical approval was obtained from both the National Research Ethics Review Committee at the Ministry of Science and Technology of Ethiopia (3.10/825/05) and the Regional Ethical Review Board at Lund University, Sweden (2010/672). Written informed consent was obtained from all participants at inclusion in the cohort study.
RESULTS
Participant Characteristics
The characteristics of study participants at the time of sampling 
Individual Inflammation Markers in Respect to Active Tuberculosis
Plasma concentrations of investigated markers are shown in Table 2 , and differences are graphically presented in Figure  1 . With the exception of IL-12p70, HIV + /TB + subjects had significantly higher levels of all markers compared with HIV + / TB − (all P < .01). The difference between HIV + /TB + and HIV + / TB − were most pronounced for CRP (median concentration, 27.9 vs 1.8 mg/L; P < .001), suPAR (median concentration, 2.6 vs 1.1 ng/mL; P < .001), and IL-6 (median concentration, 9.7 vs 2.1 ng/L; P < .001). The IL-27 and IL-12-p70 concentrations could not be extrapolated due to large proportions of values below the standard curve; therefore, these markers were excluded from further analyses. We compared levels of inflammatory markers with regard to bacteriological results (reflecting bacterial load in sputum) and presence of TB symptoms. Levels of CRP, IL-6, IL-18, IP-10, PCT, and suPAR were significantly higher in Xpert MTB/RIF-positive HIV (Table 2) . Adjustments for CD4 cell count in logistic regression did not significantly change the odds ratio for any marker ( Table 3) .
Correlation of Inflammation Markers to Other Parameters
Because the incidence of active TB increases with HIV-related immunosuppression, we determined whether biomarker levels were independently associated with TB or with surrogate markers of HIV disease progression. For this purpose, we performed logistic regression with adjustments for CD4 cell count. This did not significantly change the odds ratio for any marker (Table 3 ). In addition, Spearman's rank-order correlations were performed between plasma levels of each marker and CD4 cell count and HIV-RNA levels, respectively. When the results from all 260 study participants were analyzed, all markers, except CCL5, exhibited significant inverse Spearman rank correlations to CD4 cell count (ρ: −0.34 to −0.41, all P < .01). The same markers were significantly inversely correlated to CD4 cell count in separate analysis of HIV + /TB + subjects (ρ: −0.22 to −0.52, all P < .05).
Among HIV + /TB − subjects, IL-18 (ρ: −0.29, P < .01) and IP-10 (ρ: −0.35, P < .01) were significantly inversely correlated to CD4 cell count, whereas other markers did not show such correlation.
When assessed for correlation with HIV-RNA levels, IL-6 (ρ: 0.2, P < .01), IL-18 (ρ: 0.27, P < .01), IP-10 (ρ: 0.43, P < .01), and suPAR (ρ: 0.2, P < .01) exhibited significant correlation when all subjects were included. In HIV + /TB + subjects, IL-18 (ρ: 0.34, P < .01), IP-10 (ρ: 0.42, P < .01), and suPAR (ρ: 0.27, P < .01) correlated to HIV RNA, whereas only IP-10 exhibited significant correlation among HIV + /TB − subjects (ρ: 0.4, P < .01)
( Tables 1 and 12 ; Supplementary Material). C-reactive protein and PCT were higher in male subjects (P < .01; median 10 vs 4 mg/L and 74 vs 44 pg/mL, respectively). Marker levels were not significantly altered in the 15 subjects who had received TB treatment before collection of samples.
Discriminatory Potential of Inflammation Markers for Tuberculosis
To explore the discriminatory potential for TB identification, ROC curves were constructed for both individual markers and combinations of markers. Although CRP had the best discriminatory potential among the markers investigated, 24% of HIV + /TB + subjects had CRP levels <5 mg/L, and 29% had levels <10 mg/L. Hence, using previously suggested cutoffs of 10 or 5 mg/L in this population would result in a sensitivity of 71% or 76%, respectively. Because a high proportion of HIV + /TB + subjects in this population had CRP levels <5 mg/L, a cutoff with the requested 90% sensitivity would be as low as 1.2 mg/L. Figure 2 shows the distribution of CRP among HIV + /TB + subjects. Median CRP levels were low in asymptomatic subjects (1.0 mg/L) and in subjects in whom TB was only detected by liquid culture (smear and Xpert negative; 9.1 mg/L).
In logistic stepwise regression analysis, 2 markers, CRP and suPAR, remained independently associated with TB (both P < .001). The AUC of this combination was 0.83 (CI, 0.78-0.88). In subjects with CD4 cell count <200 cells/mm 3 , the AUC for this combination was 0.93 (CI, 0.87-0.97). For ROC curves of CRP and suPAR alone and in combination, see Figure 3 .
DISCUSSION
In this nested case-control study, based on a large cohort of ART-naive PLHIV subjected to intensified TB case finding, we hypothesized that profiles of inflammatory markers could distinguish individuals with active TB. Indeed, plasma levels of most inflammatory markers investigated were significantly elevated in participants with active TB compared with those without TB, with the most prominent differences found for CRP, suPAR, and IL-6.
A potential confounder for associations with TB in HIVpositive individuals is the degree of immunosuppression, which is linked to the risk of active TB. For this reason, we correlated levels of inflammatory markers to CD4 cell counts. Although most investigated markers showed inverse correlation to CD4 cell count, the relationships to TB coinfection remained significant after adjustment for this factor. Most notably, we observed that the associations with CD4 cell count differed with regard to TB coinfection. Whereas inverse correlation with CD4 cell count was observed for several markers among HIV + /TB + subjects, only IP-10 and IL-18 showed such an association in HIV + /TB-patients. Both of these markers have previously been associated with HIV disease progression [22, 23] . The finding of lower CD4 cell counts in HIV + /TB + subjects may be explained by the increasing risk of TB in relation to decreasing CD4 count [24] , but this could also be due to mechanisms related to TB disease per se, such as redistribution of CD4 cells [25, 26] .
In agreement with previous reports, we found that CRP, suPAR, and IL-6 had the strongest associations with active TB [10-13, 16, 27-29] . Interleukin-6 has been suggested as a potential biomarker for TB [27, 28, 30] . However, in our study, IL-6 did not add discriminative capacity in multivariate analysis, which might be due to covariance with CRP (Spearman's ρ: 0.7).
Currently, CRP appears to be the most promising biomarker for TB screening [29] . In addition, point-of-care assays for CRP testing are available. Its performance for this purpose has been validated among both TB suspects and PLHIV in cohorts from South Africa and Uganda [10-12, 15, 29] . Our results, showing an overall AUC of 0.80, support the discriminative capacity of CRP for TB identification. In a recent prospective cohort study, Yoon et al [13] found an AUC of 0.81 for a cutoff of 10 mg/L, with 90.2% sensitivity and 69.6% specificity. Although we did not aim to define a cutoff level for TB identification, a threshold value of 10 mg/L had considerably reduced sensitivity in our population. Median CRP levels in HIV + /TB + subjects in our cohort were lower than those reported by Yoon et al [13] (median CRP for HIV + /TB + 28 mg/L compared with 52 mg/L, respectively); with 29% having CRP levels <10 mg/L. In agreement with Lawn et al [10] , we observed that CRP levels varied with regard to bacteriological TB results, reflecting bacterial load in sputum. Persons with paucibacillary TB (Xpert negative, culture positive) had lower median CRP levels (9.1 mg/L compared with 50 mg/L in Xpert-positive patients). We have previously reported that HIV + /TB + individuals with negative Xpert and smear microscopy results had less advanced disease characteristics, and they were often asymptomatic [31] . However, despite ART initiation before establishment of TB diagnosis and delayed initiation of TB therapy, these patients did not have inferior treatment outcomes. Similar observations have been made by other researchers among HIV-positive persons living in TB-endemic settings [32, 33] . It is plausible that these cases represent early active TB, and that the inflammatory response characteristic of HIV/TB coinfection is not fully evolved. Accurate identification of early asymptomatic active TB is challenging by clinical examination as well as radiology and bacteriological methods. Our findings also show low levels of inflammatory markers (including CRP) in the small number of patients with asymptomatic TB (9 of 130), implying that CRP screening may be inadequate in this situation. Similar to our study, Shapiro et al [15] recently reported inadequate performance for CRP screening using a cutoff of 10 mg/L. However, these investigators found a sensitivity of 90.5% using a cutoff level of 5 mg/L. The corresponding sensitivity for this cutoff in our population was <80%. These results suggest that CRP, although strongly associated with active TB, might not optimally identify all TB + /HIV + cases as a single
biomarker. An alternative option for TB identification among PLHIV might be the use of combinations of biomarkers. Apart from CRP, suPAR showed strong independent discriminative capacity. Besides associations with increased mortality in several conditions, including both HIV [34, 35] and TB [36] , elevated suPAR levels have been associated with TB coinfection in PLHIV [36, 37] . Although both CRP and suPAR individually had discriminative performance in our population, a combination of both these markers showed higher discriminatory capacity than when either marker was used separately. The best performance was found in subjects with severe immunosuppression (CD4 <200 cells/mm 3 ; AUC = 0.93). These results imply a potential for improved identification of TB using a combination of biomarkers, especially in this subset of patients who represent those at highest risk of TB. The combination might be constructed as a composite score; alternatively, the combination could be used as a 2-step process, in which subjects with low CRP levels are further investigated with suPAR. Further studies are required (1) to define optimal cutoff levels and (2) to validate the proposed combination of CRP and suPAR prospectively in different populations before it is implemented in clinical care. Our results support the concept of combining biomarkers for TB identification, and further studies, based on relevant clinical populations, are indicated. Although other markers investigated did not show adequate discriminatory capacity as biomarkers for TB screening, we did observe significant differences related to TB coinfection. Two of those markers, IP-10, a chemokine secreted after IFN-γ stimulation [38] , and IL-18, which promotes IFN-γ secretion by T cells [39] , were both associated with active TB and with CD4 cell count. Previous studies have linked levels of IP-10 and IL-18 to accelerated HIV disease progression [22, 23] . Whereas IP-10 has been evaluated as a TB biomarker in both HIV-negative and HIV-positive subjects [30, 40, 41] , the association between IL-18 and active TB in PLHIV has not previously been investigated to our knowledge.
Three additional markers (CCL5, PCT, and IL-27) were significantly elevated in HIV + /TB + subjects, but their performance for TB identification was relatively low. Whereas most studies indicate that TB only leads to slightly elevated PCT [42, 43] , raised levels of PCT have been associated with poor prognosis in TB patients [43] . Thus, PCT may serve as a prognostic marker in cases with established TB diagnosis. Although IL-27 may promote differentiation of IFN-γ-producing Th1 cells, it appears to favor bacterial survival in the setting of mycobacterial infection [44] , possibly by suppressing T-cell migration into infected tissue [45] . It has been suggested as a biomarker for TB in pleural effusions [46] , and it has previously been shown to be elevated in plasma from TB subjects [45, 47] . We observed differences in the distribution of CRP and PCT with regard to gender, with significantly higher median levels in men than women. Similar findings with regard to CRP in TB have been reported in a study by Lawn et al [10] , where male gender was associated with CRP >50 mg/L. This phenomenon might reflect later presentation and more advanced TB and HIV disease at inclusion among men. Indeed, the male subjects had higher viral load, lower CD4 cell count, and higher proportion sputum smear and Xpert MTB/RIF-positive results, albeit none of these findings were significant. Chavez et al [48] described different cytokine profiles between males and females with TB. It is possible that different biomarkers are optimal for TB screening in men and women.
A major strength of this study was access to samples from a large prospective cohort of ART-naive PLHIV, in which all subjects had been systematically investigated for active TB. In particular, this allowed for inclusion of HIV-positive controls in whom active TB was excluded at inclusion and who were followed for 6 months without displaying clinical manifestations suggestive of active TB. Hence, we consider the risk of misclassification to be minimal. Furthermore, we explored a range of potential biomarkers for TB, including several that have not previously been investigated for the purpose of TB identification among PLHIV. We also correlated the levels of these biomarkers to CD4 cell counts and HIV-RNA levels, to determine whether the associations with TB were explained by more advanced HIV disease and not directly related to TB coinfection.
Although we assessed a panel of TB-associated immune markers and explored the possibility of combing these, other markers involved in the host response to TB infection might increase the discriminatory capacity. With regard to the laboratory analyses, high interassay variability occurred for some markers, especially suPAR. However, MFI values were consistent between runs, and the results in concentrations correspond well to the MFI results in terms of discriminatory capacity (Supplementary Figure 1) . In addition, samples were handled randomly in plates containing both HIV aim to define cutoff levels for clinical use in this exploratory study of potential biomarkers. This will be necessary to translate these results into clinical practice.
CONCLUSIONS
We found significant differences in the inflammatory profiles in HIV-positive ART-naive individuals with regard to concomitant active TB. Whereas CRP had the strongest discriminatory potential for TB identification as a single marker, 29% of subjects with bacteriologically confirmed active TB had CRP below the previously proposed cutoff level of 10 mg/L The best discriminative performance was observed for a combination of CRP and suPAR, suggesting a potential for combinations of biomarkers for TB screening among PLHIV.
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